Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open in red
Tue, 15 Sep 09:30 am

The major Asian stock markets have opened the day on a disappointing note. Stock markets in China, Indonesia and Singapore are down by 2.3%, 1.1% and 1% respectively. The major stock indices in the Europe and in US ended their previous session in red. The rupee is trading at 66.37 per US dollar.

Indian stock markets have opened below the dotted line. BSE-Sensex is trading down by 44 points (down 0.2%) and NSE-Nifty is trading down by 23 points (down 0.3%). However S&P BSE Midcap and S&P BSE Midcap have opened in green. Both the indices are trading up by 0.3% and 0.2% respectively. Sectoral indices have opened the day on a mixed note with stocks from pharmaceutical and FMCG sector witnessing maximum buying interest. However stocks from telecommunication are the top losers in the pack

An article on a financial daily reports, close to half the country is experiencing deficient rainfall. The overall deficit has gone up by 16%. According to the data published by the Indian Meteorological Department (IMD), 44% of the country has received deficient rainfall and 50% has witnessed normal rainfall. Delhi, Haryana, Chandigarh have recorded deficiency of 40%. However the fresh spell of rains last week in parts of central India has brought down the deficiency in several parts. According to Skymet, the monsoon in India is likely to take another week to begin its withdrawal from Delhi-NCR, Punjab and other parts of northwest India.

Stocks in the pharmaceutical sector are trading on a positive note. As per an article in Economic Times, Sun Pharma is looking forward to acquire US based company Insite Vision Inc. Insite Vision is a specialty ophthalmologic product developer which are used for the treatment of the eye-related disease. Reportedly, Insite is also expecting a new drug discovery approval from the US FDA for two of its drugs namely- BromSite and DexaSite in the medium term. Sun Pharma has made a bid for Insite Vision at an equity valuation of close to Rs 3bn. Stock of Sun Pharma is trading up by 0.8%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.